雜志介紹

Biomarkers In Medicine雜志介紹

《Biomarkers In Medicine》是一本以English為主的未開放獲取國際優(yōu)秀期刊，中文名稱醫(yī)學(xué)生物標(biāo)志物，本刊主要出版、報道醫(yī)學(xué)-MEDICINE, RESEARCH & EXPERIMENTAL領(lǐng)域的研究動態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗和科研成果，介紹該領(lǐng)域有關(guān)本專業(yè)的最新進展，探討行業(yè)發(fā)展的思路和方法，以促進學(xué)術(shù)信息交流，提高行業(yè)發(fā)展。該刊已被國際權(quán)威數(shù)據(jù)庫SCIE收錄，為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動作用，也得到了本專業(yè)人員的廣泛認可。該刊最新影響因子為1.9，最新CiteScore 指數(shù)為3.8。

本刊近期中國學(xué)者發(fā)表的論文主要有：

• Association of TLR4 and TLR9 gene polymorphisms with the risk and progression of cervical lesions in HPV-infected women

  Author: Zhang, Chunlin; Yang, Zhiping; Luo, Ping; Ye, Mengxia; Gong, Ping; Gong, Quan; Mei, Bing

• Pretreatment soluble Siglec-5 protein predicts early progression and R-CHOP efficacy in diffuse large B-cell lymphoma

  Author: Sun, Xiaoqing; Cao, Jianghua; Sun, Peng; Yang, Hang; Li, Huan; Ma, Wenjuan; Wu, Xianqiu; He, Xiaohua; Li, Jing; Li, Zhiming; Huang, Jiajia

• Low expression of MEOX2 is associated with poor survival in patients with breast cancer

  Author: Wang, Huxia; Tang, Yanan; Wang, Meixia; Zhao, Jing; Ding, Caixia; Yang, Xiaomin; Han, Pihua; Liu, Peijun

• Association between CYP19A1 rs6493497 and rs936306 polymorphisms and depression susceptibility in the Chinese population

  Author: Peng, Qiuju; Yan, Yuan; Yan, Huacheng; Xie, Guibo; Shi, Lei; Wen, Yuguan; Chang, Qingxian

英文介紹

Biomarkers In Medicine雜志英文介紹

Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory.

Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice.

As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications.

Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest.

Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.